Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial (Clin Res Cardiol, (2017), 106, (444–456), 10.1007/s00392-016-1074-x);Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial

Clinical Research in Cardiology

Volumn 106, Issue 6, 2017, Pages 444-456

  Filippatos, Gerasimos ^a,l   Farmakis, Dimitrios ^a   Metra, Marco ^b   Cotter, Gad ^c   Davison, Beth A ^c   Felker, G Michael ^d   Greenberg, Barry H ^e   Hua, Tsushung A ^f   Pang, Peter S ^g   Ponikowski, Piotr ^h   Qian, Min ⁱ   Severin, Thomas A ^f   Voors, Adriaan A ^j   Teerlink, John R ^k  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Momentum Research Inc   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁱ Columbia University ^*  (United States)

^j UNIVERSITY OF GRONINGEN   (Netherlands)

^k SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

Acute heart failure; Atrial fibrillation; Relaxin; Serelaxin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SERELAXIN; TROPONIN T; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; AGED; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE MONITORING; BODY MASS; BREATHING RATE; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; COMORBIDITY ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FLUTTER; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY INJURY; LIVER DISEASE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MODERATE HEPATIC IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SOMNOLENCE; TREATMENT OUTCOME; UREMIA; VISUAL ANALOG SCALE; COMPLICATION; HEART FAILURE; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BIOMARKERS; CARDIOVASCULAR AGENTS; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RELAXIN; STROKE; TREATMENT OUTCOME;

EID: 85011295569     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-017-1139-5     Document Type: Erratum

References (32)

1. Alla F, Zannad F, Filippatos G (2007) Epidemiology of acute heart failure syndromes. Heart Fail Rev 12:91–95
2. Farmakis D, Parissis J, Filippatos G (2015) Acute heart failure: epidemiology, classification and pathophysiology. In: The ESC textbook of intensive and acute cardiovascular care, 2nd edn. Oxford University Press, Oxford, p 800
3. Bueno H, Ross JS, Wang Y, Chen J, Vidan MT, Normand SL, Curtis JP, Drye EE, Lichtman JH, Keenan PS, Kosiborod M, Krumholz HM (2010) Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure 1993–2006. JAMA 303:2141–2147
4. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G (2015) Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 17:544–558
5. Gheorghiade M, Filippatos G, Felker M (2012) Diagnosis and management of acute heart failure syndromes. In: Bonnow RO, Mann DL, Zipes DP, Libby P (eds) Braunwald’s heart disease, 9th edn. Elsevier, Philadelphia, pp 517–542
6. Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT, van der Harst P, Rienstra M, van Gelder IC, van Veldhuisen DJ, van Gilst WH, van der Meer P (2015) Sex differences in new-onset heart failure. Clin Res Cardiol 104(4):342–350
7. Ogah OS, Davison BA, Sliwa K, Mayosi BM, Damasceno A, Sani MU, Mondo C, Dzudie A, Ojji DB, Kouam C, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Cotter G (2015) Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: results of the THESUS-HF study. Clin Res Cardiol 104(6):481–490
8. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G (2015) Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail 17:570–582
9. Efremidis M, Pappas L, Sideris A, Filippatos G (2008) Management of atrial fibrillation in patients with heart failure. J Card Fail 14:232–237
10. Richards M, Di Somma S, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Clopton P, Filippatos GS, Anand I, Ng L, Daniels LB, Neath SX, Shah K, Christenson R, Hartmann O, Anker SD, Maisel A (2013) Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail 1:192–199
11. Letsas KP, Filippatos GS, Pappas LK, Mihas CC, Markou V, Alexanian IP, Efremidis M, Sideris A, Maisel AS, Kardaras F (2009) Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol 98:101–106
12. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:2071–2104
13. Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D (2014) The prognostic significance of atrial fibrillation in heart failure with a preserved and reduced left ventricular function: insights from a meta-analysis. Eur J Heart Fail 16:1317–1322
14. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39
15. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR, Investigators RA (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61:196–206
16. Felker GM, Teerlink JR, Butler J, Hernandez AF, Miller AB, Cotter G, Davison BA, Filippatos G, Greenberg BH, Ponikowski P, Voors AA, Hua TA, Severin TM, Unemori E, Metra M (2014) Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol 64:1591–1598
17. Liu LC, Voors AA, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Chen Y, Greenberg BH, Ponikowski P, Pang PS, Prescott MF, Hua TA, Severin TM, Metra M (2016) Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Clin Res Cardiol 105(9):727–737
18. Schmieder RE, Mitrovic V, Hengstenberg C (2015 Aug) Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. Clin Res Cardiol 104(8):621–631. doi:10.1007/s00392-015-0839-y (PubMed PMID: 25787721)
19. Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Hua TA, Severin T, Unemori E, Voors AA, Teerlink JR (2013) Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 34:3128–3136
20. Miró Ò, Gil V, Müller C, Mebazaa A, Bueno H, Martín-Sánchez FJ, Herrero P, Jacob J, Llorens P (2015) How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry. Clin Res Cardiol 104(10):850–860
21. Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA. Design of the RELAXin in acute heart failure study. Am Heart J 2012;163:149–55 e1.
22. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, Kamel H (2014) Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 312:616–622
23. Healey JS, Connolly SJ, Gold MR, Israel CW, van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, Investigators A (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120–129
24. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, van Gelder IC, Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, Healey JS, Investigators A (2014) Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 129:2094–2099
25. Farmakis D, Parissis J, Filippatos G (2014) Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 63:945–953
26. Milia P, Caserio M, Bani D, Rastelli TF, Sonaglia F, Bigazzi B, Bigazzi M (2013) Efficacy of relaxin on functional recovery of post stroke patients. Ital J Anat Embryol 118:92–97
27. Wilson BC, Connell B, Saleh TM (2006) Relaxin-induced reduction of infarct size in male rats receiving MCAO is dependent on nitric oxide synthesis and not estrogenic mechanisms. Neurosci Lett 393:160–164
28. Wilson BC, Milne P, Saleh TM (2005) Relaxin pretreatment decreases infarct size in male rats after middle cerebral artery occlusion. Ann N Y Acad Sci 1041:223–228
29. Bergeron LH, Willcox JM, Alibhai FJ, Connell BJ, Saleh TM, Wilson BC, Summerlee AJ (2015) Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats. Endocrinology 156:638–646
30. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M (2010) Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 7:75–82
31. Zhao Z, Ng CY, Liu T, Li H, Li G (2014) Relaxin as novel strategy in the management of atrial fibrillation: potential roles and future perspectives. Int J Cardiol 171:e72–e73
32. Parikh A, Patel D, McTiernan CF, Xiang W, Haney J, Yang L, Lin B, Kaplan AD, Bett GC, Rasmusson RL, Shroff SG, Schwartzman D, Salama G (2013) Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circ Res 113:313–321